14 recruiting, 13 completed, 7 active not recruiting, 7 terminated. 23 Phase 1, 20 Phase 2, 2 Not applicable, 1 Early Phase 1.
Follow Blastic Plasmacytoid Dendritic Cell Neoplasm: new trials by email Literature Review of Blastic Plasmacytoid Dendritic Cell Neoplasm trials Research Report on Blastic Plasmacytoid Dendritic Cell Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults CARCIK CD123/33 infusion - AML (Acute Myeloid Leukemia), BPDCN | Phase 1 / Phase 2 | Recruiting | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 18 | 2026-10-01 | 2026-10-16 |
| Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 96 | 2026-03-02 | 2026-04-13 |
| Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients Venetoclax, Tagraxofusp - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2025-12-11 | 2026-07-01 |
| A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy Chemotherapy - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Recruiting | Stemline Therapeutics, Inc. | 140 | 2025-10-17 | 2026-09-15 | |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN Anti-CD123 CAR NK cells - AML (Acute Myeloid Leukemia), BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm) | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 30 | 2024-12-12 | 2026-08-28 |
| CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial Autologous CAR123 T lymphocytes - Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma | Early Phase 1 | Active not recruiting | Institute of Hematology and Blood Transfusion, Czech Republic | 18 | 2024-10-23 | 2026-09-14 |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide - Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 54 | 2024-07-23 | 2026-10-26 |
| A Registry-study of ELZONRIS in Participants With BPDCN Tagraxofusp - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Recruiting | Stemline Therapeutics, Inc. | 80 | 2024-06-26 | 2026-08-25 | |
| SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS SENTI-202 - AML/MDS, CD33 Expressing Hematological Malignancies | Phase 1 | Active not recruiting | Senti Biosciences | 21 | 2024-04-22 | 2026-02-12 |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML | Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 54 | 2022-11-11 | 2024-12-06 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies MGD024 - Leukemia, Acute Myeloid, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | MacroGenics | 130 | 2022-07-13 | 2026-07-28 |
| Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Recruiting | Immune Oncology Research Institute | 200 | 2022-07-01 | 2026-06-05 | |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product. - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse | Terminated | Mustang Bio | 3 | 2021-09-29 | 2024-07-22 | |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) CD123-CAR T, Cyclophosphamide, Fludarabine - AML/MDS, B-ALL | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 108 | 2020-07-29 | 2026-05-19 |
| Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Cyclophosphamide, Cytarabine, Dexamethasone - Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2020-05-29 | 2026-09-14 |
Showing 20 of 45. Sign in to see all of them.
Leukemia, Myeloid, Acute (24) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Leukemia, Biphenotypic, Acute (13) · Myelodysplastic Syndromes (12) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (11) · Burkitt Lymphoma (8) · Hematologic Neoplasms (8) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Leukemia, Hairy Cell (6) · Leukemia, Myelomonocytic, Chronic (6) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (6) · Recurrence (6) · Hodgkin Disease (5) · Lymphoma, Large B-Cell, Diffuse (5)
Hemic and Lymphatic Diseases (45) · Histiocytic Disorders, Malignant (45) · Neoplasms (45) · Neoplasms by Histologic Type (45) · Neoplasms by Site (45) · Skin Diseases (45) · Skin Neoplasms (45) · Skin and Connective Tissue Diseases (45) · Hematologic Diseases (44) · Lymphoma (44) · Leukemia (41) · Hematologic Neoplasms (37) · Immune System Diseases (27) · Immunoproliferative Disorders (27) · Leukemia, Myeloid (27)
Cyclophosphamide (9) · fludarabine phosphate (7) · tagraxofusp (7) · fludarabine (6) · Whole-Body Irradiation (5) · venetoclax (5) · Methotrexate (4) · Mycophenolic Acid (4) · Calcium Dobesilate (3) · Cyclosporine (3) · Cytarabine (3) · Dexamethasone (3) · Specimen Handling (3) · Thiotepa (3) · Azacitidine (2)
Fred Hutchinson Cancer Center (8) · M.D. Anderson Cancer Center (4) · City of Hope Medical Center (3) · Mayo Clinic (3) · Stemline Therapeutics, Inc. (3) · Centre Hospitalier Universitaire de Besancon (2) · Chongqing Precision Biotech Co., Ltd (2) · Dana-Farber Cancer Institute (2) · Mustang Bio (2) · AbbVie (1) · Beijing Biotech (1) · Cellectis S.A. (1) · Fondazione Matilde Tettamanti Menotti De Marchi Onlus (1) · French Innovative Leukemia Organisation (1) · Immune Oncology Research Institute (1)
United States (33) · Italy (6) · France (4) · Germany (4) · China (3) · United Kingdom (3) · Australia (2) · Canada (2) · Spain (2) · Armenia (1) · Austria (1) · Cyprus (1) · Czechia (1) · Denmark (1) · Egypt (1)
Elizabeth Krakow (2) · Marie Bleakley (2) · Abhishek Maiti, MBBS (1) · Adam Lamble, MD (1) · Andrew Lane, MD (1) · Andrew Lane, MD, PhD (1) · Ann Dahlberg (1) · Arthur E. Frankel, MD (1) · Astghik Voskanyan, MD (1) · Bruce Dezube, M.D. (1) · David Maloney (1) · Frank Perabo, MD, PhD (1) · Gevorg Tamamyan, MD, PhD, DSc (1)
PMID 33795208, PMID 24859366, PMID 31018069, PMID 32499241, PMID 32896301, PMID 33027528, PMID 33049057, PMID 33580980, PMID 33792630, PMID 34255353, PMID 34474640, PMID 35007144, PMID 35622074, PMID 35750419, PMID 35820082, PMID 37647601, PMID 38052038, PMID 38423051, PMID 38683966, PMID 41043099, PMID 41486505, PMID 41671533, PMID 42681647
P30CA015704 (4), P01CA018029 (2), P30CA015083 (2), 2025 (1), P01CA078902 (1), P30CA016672 (1), P30CA033572 (1), R01HL121568 (1), U01CA097452 (1)